Aflibercept for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Sarwar, Salman ^a   Maya, Jose R ^a   Hanout, Mostafa ^a   Sepah, Yasir J ^a   Do, Diana V ^a   Nguyen, Quan Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

ADVERSE OUTCOME; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; WET MACULAR DEGENERATION;

EID: 84969570538     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011346     Document Type: Article

References (38)

1. Age-Related Eye Disease Study Research Group. Responsiveness of the National Eye Institute visual function questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS report no. 14. Archives of Ophthalmology 2005;123(9):1207-14.
2. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al.An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Survey of Ophthalmology 1995;39(5):367-74.
3. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1432-44.
4. Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, et al.Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011;118(6):1089-97.
5. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al.Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2011;364(20):1897-908.
6. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al.Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmology 2010;10:31.
7. Childs AL, Bressler NM, Bass EB, Hawkins BS, Mangione CM, Marsh MJ, et al.Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality-of-life findings: SST report no. 14. Ophthalmology 2004;111(11):2007-14.
8. Clemons TE, Chew EY, Bressler SB, McBee W. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Archives of Ophthalmology 2003;121(2):211-7.
9. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
10. Do DV, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, et al.Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology 2012;119(4):771-8.
11. Dong LM, Childs AL, Mangione CM, Bass EB, Bressler NM, Hawkins BS, et al.Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. American Journal of Ophthalmology 2004;138(1):91-108.
12. US Food, Drug Administration. FDA news release (2011): FDA approves Eylea for eye disorder in older people. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm (accessed 16 December 2013).
13. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. European Cytokine Network 2009;20(4):158-63.
14. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Archives of Ophthalmology 1986;104(4):513-4.
15. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al.Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 2004;122(4):564-72.
16. Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology 2013;120(5 Suppl):S3-7.
17. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, et al.The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118(6):1098-106.
18. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al.Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-48.
19. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
20. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al.VEGF-Trap: a VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences of the United States of America 2002;99(17):11393-8.
21. Hyman L, Neborsky R. Risk factors for age-related macular degeneration: an update. Current Opinion in Ophthalmology 2002;13(3):171-5.
22. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al.Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382(9900):1258-67.
23. Jansen RM. The off-label use of medication: the latest on the Avastin - Lucentis debacle. Medicine and Law 2013;32(1):65-77.
24. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. American Journal of Ophthalmology 1999;128(1):45-53.
25. Miskala PH, Bass EB, Bressler NM, Childs AL, Hawkins BS, Mangione CM, et al.Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. Ophthalmology 2004;111(11):1981-2.
26. Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Current Medical Research and Opinion 2011;27(7):1465-75.
27. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al.Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011230.pub2]
28. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
29. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al.Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1419-31.
30. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, et al.VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proceedings of the National Academy of Sciences of the United States of America 2007;104(47):18363-70.
31. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Current Opinion in Ophthalmology 2010;21(3):218-26.
32. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al.A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard. PloS One 2012;7(8):e42701.
33. Schultz DW, Klein ML, Humpert AJ, Luzier CW, Persun V, Schain M, et al.Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family. Human Molecular Genetics 2003;12(24):3315-23.
34. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3]
35. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. British Journal of Ophthalmology 2008;92(5):667-8.
36. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye 2005;19(9):935-44.
37. Wong TY, Chakravarthy U, Kelin R, Mitchell P, Zlateva G, Buggage R, et al.The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115(1):116-26.
38. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health 2014;2(2):e106-16.